ALK-Abelló A/S is a global leader in the research, development, and manufacturing of allergy immunotherapy (AIT) products. The company's core business revolves around disease-modifying treatments for respiratory allergies, offering sublingual tablets, sublingual drops, and subcutaneous injections that help patients build tolerance to allergens such as grass, tree pollen, ragweed, and house dust mites. In addition to its immunotherapy portfolio, ALK-Abelló produces allergy diagnostic solutions and emergency treatments for severe allergic reactions, including adrenaline auto-injectors and needle-free nasal sprays for anaphylaxis. The company operates across Europe, North America, and international markets, with Europe accounting for the majority of its revenue. ALK-Abelló's competitive position is supported by its extensive clinical evidence and its strategic focus on expanding patient access to convenient, tablet-based allergy treatments.
